Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446697 | 1.00 | GBA1 (0.48) | GBA1PNMTACP3AOC3MEN1 | |
| SCHEMBL3489363 | 1.00 | GBA1 (0.48) | GBA1PNMTACP3AOC3MEN1 | |
| SCHEMBL30353858 | 1.00 | GBA1 (0.48) | GBA1PNMTACP3AOC3MEN1 | |
| SCHEMBL30828721 | 1.00 | GBA1 (0.48) | GBA1PNMTACP3AOC3MEN1 | |
| Hydrochloric Acid SCHEMBL382469 | 0.98 | GBA1 (0.47) | GBA1PNMTACP3AOC3MEN1 | |
| Hydrochloric Acid SCHEMBL1440815 | 0.98 | GBA1 (0.47) | GBA1PNMTACP3AOC3MEN1 | |
| Hydrochloric Acid SCHEMBL1440813 | 0.98 | GBA1 (0.47) | GBA1PNMTACP3AOC3MEN1 | |
| Malonic Acid SCHEMBL17958979 | 0.88 | MEN1 (0.46) | GBA1ACP3MEN1KMT2ALMNA | |
| SCHEMBL25269085 | 0.84 | PNMT (0.47) | GBA1PNMTACP3AOC3MEN1 | |
| SCHEMBL382070 | 0.84 | PNMT (0.47) | GBA1PNMTACP3AOC3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | ASANA BIOSCIENCES, LLC | 2023-01-26 | — | — | US | claimed |
| WO-2021086726-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | Asan BioSciences, LLC (US) | 2021-05-06 | — | — | WO | claimed |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2020-06-11 | — | — | US | claimed |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2019-11-12 | — | — | US | claimed |
| EP-3307727-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | Asana BioSciences, LLC (US) | 2018-04-18 | — | — | EP | claimed |
| US-9896445-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | Ansana BioSciences, LLC (US) | 2018-02-20 | — | — | US | claimed |
| US-20170362216-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATEMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2017-12-21 | — | — | US | claimed |
| WO-2016205418-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-22 | — | — | WO | claimed |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-15 | — | — | US | claimed |
| EP-4743460-A1 | CRYSTALLINE FORM OF (S)-1-(1- (3-CHLOROPHENYL)-2-(DIMETHYLAMINO) ETHYL)-4- (5 -MORPHOLINO -1H-PYRROLO[2,3-B]PYRIDIN -3-YL)PYRIDIN-2 (1H)-ONE, ITS PREPARATION AND ITS USE AS ERK KINASE INHIBITOR | AGV Discovery (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743461-A1 | (S)-1-(1- (3-CHLOROPHENYL)-2-(DIMETHYLAMINO) ETHYL)-4-(5 -MORPHOLINO-1H- PYRROLO[2,3-B]PYRIDIN-3-YL) PYRIDIN-2(1H)-ONE,THEIR PREPARATION AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-1651611-A2 | BENZIMIDAZOLE C-2 HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005082885-A1 | IMIDAZOLE BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1545543-A2 | NOVEL TYROSINE KINASES INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005021510-A2 | BENZIMIDAZOLE C-2 HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040220200-A1 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | GBA1 3683/4885PNMT 2501/4885ACP3 3489/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | GBA1 738/4885PNMT 4585/4885ACP3 3048/4885 |
| US-20170362216-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATEMENT OF CANCER | KRAS, NRAS, RAF1 | GBA1 2865/4885PNMT 3277/4885ACP3 3478/4885 |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | GBA1 2818/4885PNMT 3014/4885ACP3 3749/4885 |
| US-20040220200-A1 | Compositions useful as protein kinase inhibitors | PRKCH, MAP3K20, PACSIN2 | GBA1 1837/4885PNMT 4094/4885ACP3 644/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | GBA1 798/4885PNMT 4702/4885ACP3 1986/4885 |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | GBA1 2818/4885PNMT 3014/4885ACP3 3749/4885 |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | GBA1 2818/4885PNMT 3014/4885ACP3 3749/4885 |
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | KRAS, NRAS, BRAF | GBA1 1999/4885PNMT 4094/4885ACP3 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.